CN EN

news

Shanghai, September 25, 2023 – Lynk Pharmaceuticals representatives Dr. Michael Vazquez, Executive Vice President and Head of Chemistry, Dr. Xiaodong Li, Senior Director of Chemistry, and Dr. Lin Su, Principal Investigator, visited the BioDuro-Sundia Zhangjiang R&D Center in Shanghai recently to present the onsite chemistry team with the Lynk Pharmaceuticals Long-Term Outstanding Service Award. BioDuro-Sundia representatives Dr. Xiang Li, President of the Drug Discovery Department, Dr. Jiong Chen, Senior Vice President of Chemistry, Dr. Feng Wang, Director of Chemistry, Zhou Xin, Chemistry Team Leader, and other members were honored to attend the ceremony and receive this award.

Lynk Pharmaceuticals is a clinical stage new drug development company dedicated to the treatment of tumors and autoimmune diseases by developing small molecule innovative drugs with ‘First-in-Class’ and ‘Best-in-Class’ potential. So far this year, Lynk has achieved several new drug discovery and development milestones, including having reached a commercial strategic cooperation with Simcere for LNK01001, which has obtained positive top-line data in the Phase II clinical trial for the treatment of ankylosing arthritis. The Phase Ib clinical study of LNK01004 for the treatment of atopic dermatitis has completed its first phase, patient administration, etc. 

Dr. Michael Vazquez praised the BioDuro-Sundia chemistry team’s efficient service capabilities, "I am very happy to find such an efficient and high-quality example of project management and thank the BioDuro-Sundia chemistry team for demonstrating continuous dedication to accelerate the progress of a number of Lynk compounds into the clinic." Lynk Pharmaceuticals and BioDuro-Sundia anticipate strengthened future cooperation between the two companies.

BioDuro-Sundia representative Dr. Xiang Li, President of the Drug Discovery Department, expressed gratitude to Lynk Pharmaceuticals for initiating this ceremony of mutual recognition and trust, "BioDuro-Sundia is pleased to become close partners with Lynk Pharmaceuticals, a partnership that has grown stronger since its establishment, to advance the R&D and manufacturing of Lynk’s new drug programs." BioDuro-Sundia celebrates Lynk Pharmaceuticals’ recent developments and is pleased to offer a unique one-stop drug R&D service platform to accelerate drug pipeline R&D activities and support Lynk's new drug programs to timely completion. BioDuro-Sundia extends avid support of Lynk Pharmaceuticals’ future development of innovative therapies for the benefit of patients around the world!

BioDuro-Sundia’s commitment is to provide global biopharmaceutical companies with a complete one-stop service platform for new drug R&D services and professional technical support. Equipped with advanced research facilities and a team of more than 1,200 professional chemists, the BioDuro-Sundia Chemistry Department has provided drug R&D services at different stages for more than 330 pharmaceutical companies around the world, including many of the world's top 20 pharmaceutical companies and advanced biotechnology startups. Looking ahead, BioDuro-Sundia takes a quality-first approach and treats each program with care. BioDuro-Sundia works together with clients to synergize and innovate, to achieve win-win situations, and to move forward together.

About BioDuro-Sundia 

BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 9 global sites across 6 cities. 

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines. For more information, please visit www.bioduro-sundia.com

Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
0.164505s
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all